-+ 0.00%
-+ 0.00%
-+ 0.00%

InnoCare wins China IND approval for ICP-B161 bispecific antibody in autoimmune diseases

PUBT·10/12/2026 00:30:19
Listen to the news
InnoCare wins China IND approval for ICP-B161 bispecific antibody in autoimmune diseases
  • China’s NMPA Center for Drug Evaluation cleared InnoCare’s IND for ICP-B161, enabling clinical trials in autoimmune diseases including IBD.
  • ICP-B161 is a bispecific antibody targeting TL1A and IL-23p19, positioned as a long-acting candidate designed for less frequent dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610112030PRIMZONEFULLFEED9843518) on October 12, 2026, and is solely responsible for the information contained therein.